Harvard Bioscience (HBIO) Tops Q4 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Harvard Bioscience Reports First Quarter 2016 Financial Results
May 12, 2016 6:01 AM EDTHOLLISTON, Mass., May 12, 2016 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the Company), a global developer, manufacturer and marketer of a broad range of solutions to advance life science, reported its financial results for the three months ended March 31, 2016.
The Company reported revenues for the first quarter of $27.0 million and non-GAAP diluted earnings per share of $0.05, compared with revenues of $25.8 million and non-GAAP earnings per diluted share of $0.02 for the year-ago quarter. For the respective diluted earnings per share figures under U.S. generally accepted accounting principles (GAAP) that correspond to the... More
